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Abstract
Aims This study aimed to describe baseline characteristics of patients with atrial fibrillation (AF) at risk of stroke with and
without history of heart failure (HF) and report 2-year outcomes in the dabigatran-treated subset of a prospective, global, ob-
servational study (GLORIA-AF).
Methods and results Newly diagnosed patients with AF and CHA2DS2-VASc score ≥ 1 were consecutively enrolled. Baseline
characteristics were assessed by the presence or absence of HF diagnosis at enrolment. Incidence rates for outcomes in
dabigatran-treated patients were estimated with and without standardization by stroke (excluding HF component) and bleed-
ing risk scores. A total of 15 308 eligible patients were enrolled, including 15 154 with known HF status; of these, 3679 (24.0%)
had been diagnosed with HF, 11 475 (75.0%) had not. Among 4873 dabigatran-treated patients, 1169 (24.0%) had HF, and
3658 (75.1%) did not; the risk of stroke was high (CHA2DS2-VASc score ≥ 2) for 94.3% of patients with HF and 85.8% without,
while 6.0% and 7.0%, respectively, had a high bleeding risk (HAS-BLED ≥ 3). Incidence rates of all-cause death in
dabigatran-treated patients with and without HF, standardized for CHA2DS2-VASc and HAS-BLED scores, were 4.76 vs. 1.80
per 100 patient years (py), with roughly comparable rates of stroke (0.82 vs. 0.60 per 100 py) and major bleeding (1.20 vs.
0.92 per 100 py).
Conclusions Patients with AF and history of HF may have greater disease burden at AF diagnosis and increased mortality
rates vs. patients without HF. Stroke and major bleeding rates were roughly comparable between groups confirming the
long-term safety and effectiveness of dabigatran in patients with HF.
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Introduction
The relationship between atrial fibrillation (AF) and heart
failure (HF) is not yet fully understood, and further informa-
tion is needed to optimize management strategies. Overall,
AF is more prevalent in patients with vs. without HF,1 and
HF is more prevalent in patients with vs. without AF.2 A re-
cent analysis from the Framingham Heart Study identified AF
in over half of the patients with new-onset HF and HF in
over one third of patients with new-onset AF.3 In addition,
registry-based data from patients hospitalized for HF
showed that approximately 40% had a history of AF, up to
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50% had AF at baseline, and almost 20% experienced
new-onset AF during hospitalization.4 Several clinical charac-
teristics of patients with AF have been identified as potential
independent predictors of HF,2 and the two conditions share
many risk factors and pathophysiological mechanisms.5,6
However, patients with AF and HF have increased mortality
compared with patients with AF but without HF,2,3,6–8 and
both conditions predispose patients to an increased risk of
thromboembolic events.2,9,10 According to guidelines from
the European Society of Cardiology (ESC), the only therapy
with proven prognostic value for reducing risk of thrombo-
embolic events is anticoagulation, and appropriate oral anti-
coagulants should be prescribed in all patients with AF at
risk of stroke, regardless of the presence of HF.11
The ESC HF Long-Term Registry, a prospective, multicentre,
observational study of almost 15 000 patients with HF, was
published recently.12 Mean age was 66 ± 13 years, and 67%
of the patients were male. The prevalence of AF was gener-
ally age dependent in both men and women and reached
50% in patients with HF aged > 80 years.12
Four pivotal, phase 3, clinical trials (ARISTOTLE, RE-LY,
ROCKET AF, and ENGAGE AF) have shown the benefit of
non-vitamin K oral anticoagulants (NOACs) on outcomes
compared with warfarin in patients with AF.13–16 For exam-
ple, in the RE-LY trial, dabigatran etexilate (dabigatran)
110 mg twice daily showed similar rates of stroke or sys-
temic embolism (SSE) and reduced bleeding rates compared
with warfarin, while dabigatran 150 mg twice daily
showed reduced rates of SSE but similar bleeding rates.13
Moreover, the relevant benefits of dabigatran over warfarin
were consistent in patients with and without HF, as well as
in those with reduced (≤ 40%) or preserved (> 40%) left
ventricular ejection fraction (LVEF).17 A meta-analysis of
the outcomes of patients with AF and HF, using published
data from these four pivotal phase 3 trials,17–20 also
showed no interactions in the efficacy and safety of NOACs
between patients with AF both with and without HF.7 Fur-
ther data are needed from prospective, observational stud-
ies to help optimize effective management strategies and
to evaluate real-world safety and effectiveness in routine
clinical care.
GLORIA™-AF is a large, international, observational registry
programme that enrolled patients with newly diagnosed AF
at risk for stroke21 in 44 countries from five geographical re-
gions (Europe, North America, Asia, Latin America, and
Africa and the Middle East).21
Data from Phase II of GLORIA-AF, which began early after
approval of dabigatran in a given country, have been used
to compare the baseline characteristics and outcome events
at 2 years (safety and effectiveness) in the subset of
dabigatran-treated patients with AF, with or without HF at
baseline. We also describe the overall baseline clinical charac-
teristics of all patients newly diagnosed with AF, with or with-
out HF, regardless of anticoagulation treatment.
Methods
The study design has been described previously.21 In brief,
consecutively enrolled adult patients with newly diagnosed
(within 3months before the baseline visit; 4.5months in Latin
America) AF at risk of stroke (CHA2DS2-VASc scores ≥ 1,
based on the presence of congestive HF, hypertension,
age ≥ 75 years [doubled], diabetes, stroke/transient ischae-
mic attack/systemic embolism [doubled], vascular disease,
age 65–74 years, and sex category [female patients]) were in-
cluded. Patients were excluded if they had mechanical heart
valves, prior vitamin K antagonist (VKA) therapy for> 60 days,
or AF with a generally reversible cause. Patients were re-
cruited from different outpatient settings, including univer-
sity hospitals, community hospitals, specialist offices, and
general practice offices.21 Phase II of GLORIA-AF, which en-
rolled patients between November 2011 and December
2014, collected baseline data of all included patients with
AF and monitored the outcomes of those prescribed
dabigatran through 2 years of follow-up.
Eligible patients for the present analysis of baseline
characteristics were those with a baseline visit in Phase II of
GLORIA-AF and whose status with respect to the presence
or absence of HF had been recorded. HF was defined as
New York Heart Association (NYHA) classes II–IV or ejection
fraction ≤ 40%. Baseline medical history, concomitant
medications, and antithrombotic treatments prescribed were
recorded, and outcome events were collected at planned
visit intervals at 3, 6, and 12 months and 2 years after the
baseline visit.
GLORIA-AF was performed in accordance with the provi-
sions of the Declaration of Helsinki,22 and the protocol and
procedures were approved by the European Medicines
Agency, as well as relevant institutional review boards and
ethics committees where required. All patients provided writ-
ten informed consent before entering the registry.
Outcome measures
The subset of patients receiving dabigatran (defined as taking
at least one dose of dabigatran after enrolment) was
followed for up to 2 years to assess outcomes. Outcome mea-
sures were the incidence of stroke, myocardial infarction
(MI), major bleed, all-cause death and vascular death, and a
composite of SSE, MI, life-threatening bleed, and vascular
death. Occurrence of outcome measures was evaluated ac-
cording to the presence or absence of HF at baseline.
Statistical analysis
Baseline characteristics were analysed descriptively in pa-
tients with AF both with and without HF. To compare the
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clinical demography of patients with and without HF, we re-
port the standardized difference between groups.23 We con-
sidered variables with standardized differences < 10% to be
similar between the groups. Patients who were prescribed
dabigatran but did not take at least one dose (n = 14) were
excluded from the outcome analysis. Incidence rates and
95% confidence intervals (CIs) of outcomes were evaluated
according to the presence or absence of HF. In addition to
crude estimates, to eliminate the confounding effect of risk
score components (except for HF) accounting for differences
in outcomes between patients with and without HF, the inci-
dence rates were standardized by stroke [modified CHA2DS2-
VASc score (excluding prior congestive HF as a compo-
nent) < 3, 3, and >3] and bleeding risk [HAS-BLED score <
2 or ≥ 2 (excluding labile international normalized ratios)].
The HAS-BLED score is based on the presence of hyperten-
sion, abnormal renal/liver function, stroke, bleeding history
or predisposition, elderly (> 65 years), and drugs/alcohol
concomitantly. The strata for standardization were (i) CHA2-
DS2-VASc< 3 and HAS-BLED _x0003C; 2; (ii) CHA2DS2-VASc = 3
and HAS-BLED _x0003C; 2; (iii) CHA2DS2-VASc > 3 and HAS-
BLED _x0003C; 2; (iv) CHA2DS2-VASc < 3 and HAS-BLED ≥ 2;
(v) CHA2DS2-VASc = 3 and HAS-BLED ≥ 2; and (vi) CHA2DS2-
VASc > 3 and HAS-BLED ≥ 2.
Standardization involved averages of the stratum-specific
incidence rates, weighted in each stratum by the total patient
years (py) that fell in that stratum. For missing data on
HAS-BLED scores [1804 (11.8%) dabigatran-treated patients
overall; 114 (9.8%) with HF and 379 (10.4%) without HF]
and HF [46 (0.9%) dabigatran-treated patients], we used mul-
tiple imputation with chained equations24 based upon ap-
proximately 50 baseline variables including demographics
and medical history. The CIs of the standardized incidence
rates were constructed using the bootstrap method.25 All
analyses were performed using SAS software version 9.4
(SAS Institute, Inc., Cary, NC, USA).
Results
Baseline characteristics and treatment patterns
of all patients
A total of 15 308 patients with AF from Phase II of GLORIA-AF
were eligible for analysis in the full baseline set. HF status was
missing for 154 (1.0%) patients. Baseline characteristics ac-
cording to HF status were evaluated for the remaining
15 154 patients; of these, 3679 (24.3%) were diagnosed with
HF, while 11 475 (75.7%) were not. Most patients with HF
[n = 1861 (50.6%)] were classified in NYHA functional class
II; 910 (24.7%) were NYHA class III, 354 (9.6%) were NYHA
class I, and 168 (4.6%) were NYHA class IV. For 386 patients
(10.5%), NYHA class was unknown. Just over one third
(n = 1405; 38.2%) of patients with HF had LVEF ≤ 40%.
Baseline clinical characteristics and cardiovascular and anti-
thrombotic medications of all patients with and without prior
HF are as follows: the proportion of patients aged ≥ 75 years
with or without HF was similar (40.7% vs. 38.6%). Compared
with patients without HF, those with HF were more often
male (60.9% vs. 52.3%) and had higher rates of prior MI
(18.8% vs. 7.8%) and coronary artery disease (31.6% vs.
16.7%), as well as greater proportions of symptomatic
(39.5% vs. 24.6%), persistent (43.9% vs. 33.0%), and perma-
nent AF (15.2% vs. 9.7%). Patients with HF were at a higher
risk of stroke [mean (standard deviation; SD) CHA2DS2-VASc
score 3.9 (1.6) vs. 3.0 (1.4)], while the risk of bleeding was
comparable [mean (SD) HAS-BLED score 1.4 (0.9) vs. 1.4
(0.9)]. However, it should be considered that HF is part of
the CHA2DS2-VASc score, which may explain the observed dif-
ference in stroke risk. The use of antiarrhythmic and antihy-
pertensive medications was higher among patients with HF
than those without.
The most frequently prescribed antiarrhythmic medica-
tions in patients with vs. without HF were amiodarone
(17.8% vs. 10.8%) and digoxin/digitoxin (21.9% vs. 7.9%),
while β-blockers were the most frequently prescribed antihy-
pertensive (70.7% vs. 57.3%) medication. Overall anticoagu-
lant treatment patterns at baseline were similar between
patients with and without HF (Figure 1), with VKAs and
NOACs the most frequently prescribed (35.1% vs. 31.5% for
VKAs and 46.6% vs. 48.4% for NOACs). Of the NOACs,
dabigatran was prescribed in 31.8% vs. 31.9% of patients with
and without HF; rivaroxaban in 10.5% vs. 11.8%, and
apixaban in 4.3% vs. 4.7%.
Baseline characteristics and treatment patterns
of dabigatran-treated patients
A total of 4873 patients were treated with dabigatran; prior
HF disease status was unknown for 46 (0.9%) patients and
1169 (24.0%) and 3658 (75.1%) patients with or without prior
HF, respectively. Most patients with HF were NYHA functional
class II [n = 675 (57.7%)]; 289 (24.7%) were NYHA class III, 112
(9.6%) were NYHA class I, and 23 (2.0%) were NYHA class IV.
NYHA class was unknown for 70 (6.0%) patients. One third
[n = 394 (33.7%)] of the patients with HF had LVEF ≤ 40%.
Most patients treated with dabigatran were managed by
cardiologists (87.5%), followed by neurologists (4.0%),
general practitioners/primary care physicians/gerontologists
(3.4%), or others (5.1%). Dabigatran-treated patients were
followed in community hospitals (34.6%), specialists’ of-
fices (30.0%), university hospitals (23.6%), general
practitioners/primary care sites (6.4%), outpatient or
anticoagulation clinics (4.1%), or other health care facilities
(1.3%). Baseline characteristics of dabigatran-treated patients
with and without HF are presented in Table 1. The proportion
of dabigatran-treated patients aged ≥ 75 years with or
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without HF was similar (38.2% vs. 36.2%). Similar to the over-
all population, dabigatran-treated patients with vs. without
HF were more often male (60.7% vs. 54.0%), had higher rates
of prior MI (15.2% vs. 6.6%) and coronary artery disease
(29.8% vs. 15.5%), as well as greater proportions of symptom-
atic (39.6% vs. 25.7%), persistent (43.2% vs. 32.6%), and per-
manent (18.1% vs. 11.2%) AF. Dabigatran-treated patients
with HF were also at a higher risk of stroke [mean (SD) CHA2-
DS2-VASc score 3.8 (1.5) vs. 3.0 (1.4) without HF], while the
risk of bleeding was comparable [mean (SD) HAS-BLED score
1.2 (0.8) vs. 1.3 (0.9) without HF]. In both patient groups,
slightly more patients received dabigatran 150 mg than
110 mg twice daily (50.1% compared with 47.3% with HF
and 56.2% compared with 41.6% without HF). The most fre-
quently prescribed antiarrhythmics were amiodarone (22.2%
with HF and 14.8% without HF) and digoxin/digitoxin (19.9%
and 7.2%). The most frequently prescribed antihypertensive
was still β-blockers (70.9% and 60.2%). In addition to their
use as an antihypertensive, β-blockers are used to control
heart rhythm and increase cardiac action, which may account
for this observation.
Two-year follow-up of dabigatran-treated
patients
Mean therapy duration for the index dabigatran period was
18.0 ± 9.4 months. The crude and standardized incidence
rates (per 100 py) of the outcome events for
dabigatran-treated patients with and without prior HF are
shown in Table 2. The standardized incidence rates were
comparable between the groups with and without HF for
stroke (0.82 [95% CI: 0.41, 1.30] vs. 0.60 [0.40, 0.80] per
100 py, respectively), MI (0.87 [0.45, 1.37] vs. 0.40 [0.24,
0.58] per 100 py), and major bleed (1.20 [0.71, 1.77] vs.
0.92 [0.67, 1.18] per 100 py). AF patients with HF had higher
standardized incidence rates than those without HF for
all-cause death (4.76 [3.74, 5.86] vs. 1.80 [1.46, 2.16] per
100 py) and vascular death (1.92 [1.28, 2.62] vs. 0.53 [0.35,
0.74] per 100 py), as well as for the composite outcome of
SSE, MI, life-threatening bleed, and vascular death (3.37
[2.53, 4.33] vs. 1.70 [1.37, 2.06] per 100 py, respectively).
The unadjusted cumulative probability of the composite
outcome of SSE, MI, life-threatening bleed, and vascular
death in dabigatran-treated patients with and without prior
HF for 2 years of follow-up were evaluated. The Kaplan–
Meier curves suggest that the probability of this composite
endpoint was higher in AF patients with HF than in those
without HF over the 2-year follow-up period. Of note, the un-
adjusted cumulative probability of stroke or major bleeding
was comparable in dabigatran-treated patients over the
2 years of follow-up (Figure 2).
Discussion
AF and HF are associated with substantial morbidity and mor-
tality and are associated with a poor prognosis.26 In the
Fushimi AF registry, persistent AF was associated with a
higher incidence of the composite of cardiac death and HF
compared with paroxysmal AF.27 In the Framingham Heart
Study, 1470 participants developed either new AF or HF be-
tween the years 1948 and 1995. Among these participants,
a total of 383 individuals (26%) developed both AF and HF.8
In our study, baseline characteristics across all patients in
Phase II of GLORIA-AF revealed that the incidence of HF in pa-
tients with AF (24.3%) was similar to that previously reported.
Furthermore, patients with HF were more often male pa-
tients, had higher rates of prior MI and coronary artery dis-
ease, and greater proportions had symptomatic, persistent,
and permanent AF compared with those with no HF.
Similar to our findings, the EURObservational Research
Programme pilot survey on patients with AF (EORP-AF) re-
ported that patients with AF (electrocardiogram-documented
Figure 1 Overall anticoagulant treatment patterns in all patients with and without prior HF at baseline. Four patients without prior HF received other
anticoagulant medication such as a combination of OACs. Thirty-six patients (1.0%) with prior HF and 86 patients (0.7%) without prior HF received an-
tiplatelet treatment other than ASA. ASA, acetylsalicylic acid; HF, heart failure; NOAC, non-vitamin K oral anticoagulants; OAC, oral anticoagulant; VKA,
vitamin K antagonist.
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Table 1 Baseline demographic and clinical characteristics of 4827 phase 2 dabigatran-treated patients with recorded presence or absence
of prior HF
Characteristic AF with prior HF (n = 1169) AF without prior HF (n = 3658) Standardized differencea
Age 0.03
Mean (SD), years 69.9 (11.0) 70.3 (10.2)
< 75 years, n (%) 723 (61.8) 2333 (63.8) 0.04
≥ 75 years, n (%) 446 (38.2) 1325 (36.2) 0.04
Sex, n (%)
Male 709 (60.7) 1974 (54.0) 0.14
Female 460 (39.3) 1684 (46.0) 0.14
Ethnicity, n (%)b
White 870 (74.4) 2470 (67.5) 0.15
Asian 72 (6.2) 342 (9.3) 0.12
Arab/Middle East 81 (6.9) 221 (6.0) 0.04
Black/African American 11 (0.9) 28 (0.8) 0.02
Other 52 (4.4) 113 (3.1) 0.07
Body mass index, n (%)c 0.05
< 30 kg/m2 735 (62.9) 2364 (64.6) 0.04
≥ 30 kg/m2 428 (36.6) 1253 (34.3) 0.05
Medical status, n (%)
Coronary artery disease 348 (29.8) 567 (15.5) 0.35
Hyperlipidaemia 464 (39.7) 1538 (42.0) 0.05
Prior myocardial infarction 178 (15.2) 240 (6.6) 0.28
Prior stroke 94 (8.0) 480 (13.1) 0.17
Prior stroke or TIA 118 (10.1) 639 (17.5) 0.22
History of hypertension 898 (76.8) 2844 (77.7) 0.02
Prior bleeding 57 (4.9) 188 (5.1) 0.01
Diabetes mellitus 279 (23.9) 819 (22.4) 0.04
Abnormal kidney functiond 10 (0.9) 8 (0.2) 0.09
CHA2DS2-VASc score 0.53
Mean (SD) 3.8 (1.5) 3.0 (1.4)
High risk (score ≥ 2), n (%) 1102 (94.3) 3138 (85.8) 0.29
Moderate risk (score = 1), n (%) 67 (5.7) 520 (14.2) 0.29
HAS-BLED scoree 0.08
Mean (SD) 1.2 (0.8) 1.3 (0.9)
High (score ≥ 3), n (%) 70 (6.0) 255 (7.0) 0.04
Low (score < 3), n (%) 985 (84.3) 3024 (82.7) 0.04
AF category, n (%)
Asymptomatic 212 (18.1) 1186 (32.4) 0.33
Minimally symptomatic 494 (42.3) 1532 (41.9) 0.01
Symptomatic 463 (39.6) 940 (25.7) 0.30
AF type, n (%)
Paroxysmal 452 (38.7) 2054 (56.2) 0.36
Persistent 505 (43.2) 1193 (32.6) 0.22
Permanent 212 (18.1) 411 (11.2) 0.20
Dabigatran dose, n (%)
75 mg 23 (2.0) 64 (1.7) 0.02
110 mg 553 (47.3) 1520 (41.6) 0.12
150 mg 586 (50.1) 2055 (56.2) 0.12
Other 7 (0.6) 19 (0.5) 0.01
Additional antiplatelet therapy 185 (15.8) 429 (11.7) 0.12
Medications, n (%)
Antiarrhythmics: any 531 (45.4) 1278 (34.9) 0.22
Amiodarone 259 (22.2) 541 (14.8) 0.19
Dronedarone 3 (0.3) 37 (1.0) 0.10
Verapamil 15 (1.3) 54 (1.5) 0.02
Quinidine 0 (0.0) 1 (0.0) NE
Digoxin/Digitoxin 233 (19.9) 264 (7.2) 0.38
Mexiletine 0 (0.0) 1 (0.0) NE
Propafenone 25 (2.1) 140 (3.8) 0.10
Flecainide 4 (0.3) 173 (4.7) 0.28
Diltiazem 48 (4.1) 188 (5.1) 0.05
Other 90 (7.7)f 144 (3.9)g 0.16
Other medications: any 1112 (95.1) 3297 (90.1) 0.19
ARBs 298 (25.5) 1058 (28.9) 0.08
ACE inhibitors 537 (45.9) 1073 (29.3) 0.35
α-blockers or other vasodilators 87 (7.4) 263 (7.2) 0.01
β-blockers 829 (70.9) 2202 (60.2) 0.23
(Continues)
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diagnosis of AF confirmed in the year before enrolment) and
HF were more likely to have symptomatic and permanent AF
and coronary artery disease (including MI), as well as a higher
risk of stroke (CHA2DS2-VASc score ≥ 2) and bleeding risk
(HAS-BLED ≥ 3).28 However, there are differences between
GLORIA-AF and EORP-AF that may be reflected in the discrete
patient populations and perhaps variations in the timing of
the AF diagnosis in each trial (< 3months before the baseline
visit in GLORIA-AF and < 12 months before enrolment in
EORP-AF). Importantly, to be included in GLORIA-AF, patients
had to be at risk for stroke as defined by a CHA2DS2-VASc
score of at least 1. This shifts the demographic and clinical
characteristics of the group without HF, who were expected
to show higher rates of other stroke risk factors compared
with the general population of AF patients with comorbid
HF. This may explain why, in GLORIA-AF, there was little dif-
ference in mean age between the HF and no HF groups and
little difference in diabetes mellitus, while prior stroke and
transient ischaemic attack were higher in patients without
HF. When compared with EORP-AF, where AF patients were
included irrespective of stroke risk, patients with AF and HF
were older than those without HF and had higher rates of
both diabetes and prior stroke.
Within the group of patients with HF in GLORIA-AF, which
should not have been affected by the inclusion criteria, half
were classified as having NYHA class II HF and just over
one-third had reduced LVEF. In EORP-AF, almost half the pa-
tients were classified as having European Heart Rhythm Asso-
ciation class III, and over half had reduced LVEF.28 There
were also differences in anticoagulation treatment between
GLORIA-AF and EORP-AF, with additional antiplatelet therapy
given to < 16% of patients who received dabigatran in
GLORIA-AF compared with > 34% of patients in EORP-AF.28
Moreover, in GLORIA-AF, no patients reported the use of
Table 1 (continued)
Characteristic AF with prior HF (n = 1169) AF without prior HF (n = 3658) Standardized differencea
Diuretics 778 (66.6) 1144 (31.3) 0.75
Other antihypertensive agents 185 (15.8) 770 (21.0) 0.14
Statins 536 (45.9) 1593 (43.5) 0.05
Other anti-inflammatory therapy 24 (2.1)f 68 (1.9)g 0.01
AF, atrial fibrillation; ACE, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CHA2DS2-VASc, congestive HF, hy-
pertension, age ≥ 75 years (doubled), diabetes, stroke/TIA/systemic embolism (doubled), vascular disease, age 65–75 years, and sex cat-
egory (female); CHF, congestive HF; HAS-BLED, hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition,
elderly (> 65 years), drugs/alcohol concomitantly; HF, heart failure; NE, not evaluated; SD, standard deviation; TIA, transient ischaemic
attack.
Around 46 (0.9%) dabigatran patients had unknown or missing history of prior CHF.
aStandardized differences ≥ 10% (or ≥ 0.1) indicate a difference between the compared groups.
bData missing for 83 (7.1%) patients with HF and for 484 (13.2%) patients without HF. “Other” race category includes American Indian/
American Native/Alaskan Native, African, and Other.
cData missing for 6 (0.5%) patients with HF and for 41 (1.1%) patients without HF.
dAbnormal kidney function is defined as the presence of chronic dialysis or renal transplantation or serum creatinine ≥ 200 μmol/L.
eData missing for 114 (9.8%) patients with HF and for 379 (10.4%) patients without HF.
fPercentages based on the total number of eligible patients with prior HF.
gPercentages based on the total number of eligible patients with no prior HF.
Table 2 Clinical outcomes in phase 2 patients treated with dabigatran by recorded presence or absence of prior HF
Outcome
Standardizeda incidence rates per 100 py (95% CI)
With prior HF Without prior HF
Stroke 0.82 (0.41, 1.30) 0.60 (0.40, 0.80)
Major bleed 1.20 (0.71, 1.77) 0.92 (0.67, 1.18)
MI 0.87 (0.45, 1.37) 0.40 (0.24, 0.58)
All-cause death 4.76 (3.74, 5.86) 1.80 (1.46, 2.16)
Vascular death 1.92 (1.28, 2.62) 0.53 (0.35, 0.74)
Composite outcome of SSE, MI, life-threatening bleed, and vascular death 3.37 (2.53, 4.33) 1.70 (1.37, 2.06)
CHA2DS2-VASc, congestive HF, hypertension, age ≥ 75 years (doubled), diabetes, stroke/TIA/systemic embolism (doubled), vascular dis-
ease, age 65–75 years, and sex category (female); CHF, congestive HF; CI, confidence interval; HAS-BLED, hypertension, abnormal renal/
liver function, stroke, bleeding history or predisposition, elderly (> 65 years), drugs/alcohol concomitantly; HF, heart failure; MI, myocar-
dial infarction; py, patient-years; SSE, stroke or systemic embolism; TIA, transient ischaemic attack.
For standardized incidence rates, missing data were imputed using the multiple imputation approach (based on the entire eligible pop-
ulation), including congestive HF.
aStandardized by stroke [CHA2DS2-VASc (excluding prior CHF as a component) < 3, 3, and > 3] and bleeding risk [HAS-BLED < 2 or ≥ 2
(excluding labile international normalized ratios)], with HF and HAS-BLED missing values imputed. Only events occurring while the pa-
tient was on the first treatment regimen were considered; in case of recurrent events for one patient, only the first event was considered.
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other antithrombotic medications such as heparin or
fondaparinux, while in EORP-AF, 38.3% of the patients with
HF and 48.4% of those without HF reported the use of other
antithrombotic medications.28 Consistent with previously re-
ported regional differences in anticoagulation treatment for
stroke prevention in AF from the GLORIA-AF study,29 we
also observed regional differences in the prescription of
anticoagulation treatment between HF groups (data
not shown).
Baseline characteristics in dabigatran-treated patients with
AF were similar to the overall population included in this anal-
ysis, irrespective of anticoagulant therapy; patients with HF
showed a greater disease burden compared with those with-
out HF (e.g. fewer had asymptomatic AF and more had persis-
tent or permanent AF). Despite this higher disease burden,
the standardized incidence rates of stroke and major bleeding
in dabigatran-treated patients with AF were similar in those
with or without HF. In the randomized, phase 3 RE-LY trial,
HF was not meaningfully associated with the occurrence of
SSE (hazard ratio with vs. without HF 1.08; 95% CI: 0.89,
1.31), or major bleeding (hazard ratio 0.96; 95% CI: 0.83,
1.10).17 Moreover, for patients treated with either dabigatran
110 or 150 mg twice daily, the rates of SSE and major bleed-
ing events were unaffected by NYHA class or ≤ 40% LVEF
compared with warfarin.17 It is important to note that in
the pivotal RE-LY study, two-thirds of the patients had
pre-existing AF, and they were older and had more
comorbidities than those in GLORIA-AF.13 In addition, HF
remained a powerful independent predictor of vascular death
in RE-LY17; therefore, it is unsurprising that our analysis also
observed higher rates of mortality in patients with AF with
vs. without HF.
In the HF Long-Term Registry of the ESC, AF was progres-
sively more common with an increase in LVEF and was asso-
ciated with signs and symptoms of HF regardless of LVEF
subtype. Compared with sinus rhythm, AF was associated
with worse long-term cardiovascular outcomes across the
LVEF subtypes.12
Regional differences were observed in the proportion of
patients with AF who were diagnosed with comorbid HF, with
the highest proportion in the Middle East/South Africa and
the lowest in North America. Therefore, the low incidence
Figure 2 Kaplan–Meier curves for the cumulative probability, in dabigatran-treated patients by HF status, of stroke (A) and major bleeding (B). AF,
atrial fibrillation; HF, heart failure.
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of ACE inhibitors or ARBs and the high incidence of digitalis
could represent local strategies in different parts of the world
and how patients were treated. The observed differences in
patient characteristics could result from differences in other
patient characteristics (e.g. regional differences in age could
explain differences in the prevalence or treatment of HF) that
were not explored in this analysis.
Regarding outcomes, this subgroup analysis of the 2-year
outcomes of dabigatran in Phase II of GLORIA-AF30 is the
first prospective analysis to evaluate the effect of HF on out-
comes over 2 years of follow-up when dabigatran is used ac-
cording to local labels, providing additional insights into
newly diagnosed patients with AF who have a diagnosis of
comorbid HF. The roughly similar rates of stroke and major
bleeding with dabigatran use between patients with and
without HF provide important data from clinical practice set-
tings on the long-term safety and effectiveness of
dabigatran in HF patients. These patients were more likely
to have existing coronary artery disease, a history of MI,
and be at a higher risk of stroke. In addition, the burden
of AF was greater in patients with comorbid HF, as they
had symptomatic and persistent AF more frequently com-
pared with those without HF, suggesting that HF in patients
with AF represents a more burdensome form of AF. As ex-
pected, the use of antihypertensive, anti-HF, and antiar-
rhythmic medications was higher among patients with HF.
It is therefore unsurprising that higher standardized rates
of mortality and MI were observed in dabigatran-treated pa-
tients with AF with vs. without HF.
Clinical practice data regarding outcomes with dabigatran
in patients with HF were previously only available based on
retrospective analyses (e.g. database or health claims analy-
ses). In an analysis of elderly Medicare beneficiaries with AF,
propensity score-matched incidence rates of ischaemic
stroke and major bleeds for dabigatran-treated patients
were 1.13 and 4.27 per 100 py, respectively.31 An analysis
of two health insurance databases reported propensity
score-matched incidence rates in dabigatran-treated pa-
tients of 0.77 and 4.42 per 100 py for ischaemic stroke
and major bleeds, respectively.32 Additionally, in a study of
dabigatran-treated patients in the US Department of De-
fence claims database, propensity score-matched incidence
rates of ischaemic stroke and major bleeds were 0.92 and
3.08 per 100 py, respectively.33 Our data presented here
from a prospective, observational study design, in general,
support these findings, despite differences in study type
and patient populations.31–33
There are limitations to the study. First, due to the lim-
ited number of events observed, comparisons of outcomes
of patients with and without HF can only be adjusted for
a limited number of potential confounders. We focused
on stroke and bleeding risk scores because they are key
predictors of outcomes and aggregate multiple other vari-
ables (such as age and hypertension). Residual confounding
remains possible. Second, the follow-up included only
dabigatran-treated patients in Phase II of the GLORIA-AF
study. Consequently, no direct comparisons can be made
with other anticoagulants. However, data can be put into
perspective by using results from other non-interventional
and interventional studies. Indirect comparisons with other
studies are limited by the presence of differences in setting
(e.g. country), patient baseline characteristics, and study de-
sign. Importantly, in the ongoing Phase III GLORIA-AF global
registry programme, follow-up data will be collected from
VKA-treated patients, allowing for comparison of safety
and effectiveness.21 In this study, HF was diagnosed at
baseline based on functional classes II–IV or ejection frac-
tion < 40%, and follow-up was performed according to
the initial diagnosis. Therefore, there was potential for pa-
tients with HF at baseline and an ejection fraction of ≥
40% to be misclassified. Finally, this study compared pa-
tients with a CHA2DS2-VASc score ≥ 1 with and without
HF. As HF is a component of CHA2DS2-VASc, patients with
HF may have a score of ≤ 9 while those without HF can
only have a score of ≤ 8; thus, differences in CHA2DS2-VASc
scores cannot be interpreted. Differences in the prevalence
of risk components for patients without HF could be
distorted as patients with HF alone (CHA2DS2-VASc = 1)
could be included in GLORIA-AF, but patients without HF
need to present ≥ 1 additional stroke risk factor. Given that
for patients with HF, the proportion of patients with no ad-
ditional stroke risk factors is limited (6.6%), the analysis is
mostly about patients with HF and an additional risk factor
(CHA2DS2-VASc ≥ 2) and patients without HF and an addi-
tional risk factor (CHA2DS2-VASc ≥ 1); as a consequence,
the impact on the observed proportions of stroke risk fac-
tors should be limited. For the same reason, the standard-
ized incidence rates were standardized by a modified
CHA2DS2-VASc score that excludes HF.
Conclusions
In this analysis of GLORIA-AF Phase II, patients with AF with
comorbid HF were found to have a greater disease burden.
In the 2-year follow-up of those taking dabigatran, increased
rates of mortality were observed compared with patients
without comorbid HF. The incidence rates of stroke and ma-
jor bleeding were roughly similar between the patient groups
with and without HF, showing that the long-term safety and
effectiveness of dabigatran in patients with AF extends to
those with comorbid HF.
The increased mortality in patients with AF with comorbid
HF highlights the clinical importance of managing this
growing patient population to reduce outcomes and burden
of disease.
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